TZP 102
Alternative Names: TZP-102Latest Information Update: 14 Dec 2017
At a glance
- Originator Tranzyme
- Developer Ocera Therapeutics
- Class Macrocyclic compounds; Small molecules
- Mechanism of Action Ghrelin agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Diabetic gastroparesis
Most Recent Events
- 11 Dec 2017 Ocera Therapeutics has been acquired by Mallinckrodt
- 04 Sep 2013 No development reported - Phase-II for Diabetic gastroparesis in United Kingdom (PO)
- 04 Sep 2013 No development reported - Phase-II/III for Diabetic gastroparesis in Belgium (PO)